



Orion Half-Yearly Report January—June 2016

19 July 2016

Timo Lappalainen
President & CEO

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.


These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

Sales developed strongly in first half of the year

- Net sales and operating profit were higher than in comparative period
- Outlook estimate updated in June
- Specialty Products maintained strong growth
- In Europe generic competition to Stalevo extended more slowly than expected
- Sales of other proprietary products developed well
- New ODM-201 development project jointly with Bayer
- Early-phase research strengthened through collaboration agreements with DZNE and Asahi Kasei Pharma




Key figures



Breakdown of net sales


Group's net sales in H1/2016 were EUR 535 million

By business division



- Proprietary Products
- Specialty Products
- Animal Health
- Fermion
- Contract manufacturing & other
- Orion Diagnostica

By market area




- Finland
- Scandinavia
- Other Europe
- North America
- Other countries



Business Reviews

Pharmaceuticals business



Net sales split

EUR million	H1/16	H1/15	Change %
Proprietary Products	185	172	+8%
Specialty Products	246	223	+10%
Animal Health	38	44	-13%
Fermion	20	29	-29%
Contract manufacturing & other	19	19	-1%

- Net sales excluding branded Parkinson's drugs, Precedex and milestone payments up by 7%
- Growth in other proprietary products was able to compensate fully for the decline in net sales of branded Parkinson's drugs

Best-selling pharmaceuticals H1/2016

Product	Indication	Net sales EUR million	Change vs. H1/15
 Stalevo  Comtess  COMTan	Parkinson's disease	72	-11%
 Easyhaler [®]	Asthma, COPD	32	+27%
 dexdor	Intensive care sedative	28	+27%
 SIMDAX levosimendan	Acute decompensated heart failure	28	+7%
 Remsima [™] Infliximab	Rheumatoid arthritis, inflammatory bowel diseases	22	+161%
 DEXDOMITOR [®]  DOMITOR [®]  DOMOSEDAN [®]  ANTISEDAN [®]	Animal sedatives	12	-25%
 burana [®]	Inflammatory pain	10	-6%
 Precedex [®] (dexmedetomidine HCl injection)	Intensive care sedative	10	+19%
 Marevan [®]	Anticoagulant	9	-14%
 TREXAN [®]	Rheumatoid arthritis, cancer	9	+35%

Orion clear market leader in Finland

Finnish human pharmaceuticals market in H1/2016

Wholesale, EUR million




Orion in Finnish human pharmaceuticals market, EUR million



■ H1/2015 ■ H1/2016


Finland's biggest pharmaceutical companies in H1/2016



Specialty Products growing strongly in Scandinavia


TOP 3 Products	Net sales H1/2016 EUR million	Change vs. H1/2015
 Remsima™ Infliximab	22	+161%
 burana®	10	-6%
Marevan®	9	-14%

Net sales in key market areas in H1/2016 (EUR million)



- Remsima growth is expected to slow in second half of the year due to timing of tendering competitions

Parkinson's drugs



Market shares of Orion's branded Parkinson's drugs

	MAT3/2016	MAT3/2015
Finland ¹⁾	14%	19%
Sweden ¹⁾	7%	13%
Norway ¹⁾	15%	15%
Denmark ¹⁾	5%	13%
Germany ²⁾	8%	12%
UK ²⁾	11%	12%
United States ^{2) 3)}	2%	2%
Japan ^{1) 3)}	12%	11%



¹⁾ including sales to hospitals and retail distributors

²⁾ sales to retail distributors only

³⁾ Novartis sales area

Source: IMS Health sales statistics MAT3/2016

Easyhaler[®] product family and Simdax[®]




■ Others ■ Bufomix Easyhaler

■ Simdax

dexdor[®] intensive care sedative




European sedative market MAT3/2016*
Total market value EUR 527 million (+4%)



- Propofol EUR 348 million (+3%)
- Midazolam EUR 74 million (-2%)
- Dexmedetomidine EUR 38 million (+27%)
- Remifentanyl EUR 67 million (+5%)

*Source: IMS Health sales statistics MAT3/2016

Dexdor sales



Key clinical pharmaceutical development projects 1 / 2

Project	Indication	PHASE			Registration
Easyhaler® budesonide-formoterol ¹⁾	Asthma, COPD	I	II	III	Registration
Easyhaler® salmeterol-fluticasone ²⁾	Asthma, COPD	I	II	III	
ODM-201 (androgen receptor antagonist) ³⁾	Prostate cancer (nmCRPC)	I	II	III	
ODM-201 (androgen receptor antagonist) ³⁾	Prostate cancer (mHSPC)	I	II		
Levosimendan ⁴⁾	Low Cardiac Output Syndrome	I	II	III	
ORM-12741 (alpha-2c adrenoceptor antagonist) ⁵⁾	Alzheimer's disease	I	IIa		
Dexmedetomidine (intranasal) ⁶⁾	Treatment of pain	I	IIb		
ODM-109 (oral levosimendan)	ALS	I	II		

¹⁾ Aim is to obtain marketing authorisation for product in at least some European countries not included in decentralised marketing authorisation application process.

²⁾ Bioequivalence study ³⁾ In collaboration with Bayer

⁴⁾ Partner: Tenax Therapeutics, Inc. ⁵⁾ In collaboration with Janssen Pharmaceuticals

⁶⁾ Partner: Recro Pharma, Inc.

 = Phase completed

 = Phase ongoing

 = New project

More info about R&D projects at: <http://www.orion.fi/en/rd/orion-rd/pipeline/>


Key clinical pharmaceutical development projects 2/2

Project	Indication	PHASE			Registration
ODM-104 (more effective COMT inhibitor)	Parkinson's disease	I	II		
ODM-203 (targeted FGFR+VEGFR inhibitor)	Solid tumours	I	II		
ODM-204 (CYP17 enzyme and androgen receptor inhibitor)	Prostate cancer	I			
ODM-108 (negative allosteric modulator of TRPA1 ion channel)	Neuropathic pain				

	= Phase completed
	= Phase ongoing
	= Project discontinued

More info about R&D projects at: <http://www.orion.fi/en/rd/orion-rd/pipeline/>

Diagnostics business



- Operating profit decreased mainly due to decrease in net sales and products with lower margins accounting for higher proportion of sales
- QuikRead® tests remained the main product
- Launching of the first Orion GenRead® test system products continued

Outlook for 2016 (updated on 15 June 2016)

Net sales	Net sales are estimated to be slightly higher than in 2015 (net sales were EUR 1,016 million in 2015).
Operating profit	Operating profit excluding possible capital gains is estimated to exceed EUR 270 million (operating profit was EUR 267 million in 2015).

The new outlook estimate provided on 15 June 2016 does not include potential capital gains, such as a potential capital gain of about EUR 11 million to the Company from the potential sale of Ekokem Corporation shares owned by the Company based on the tender offer for Ekokem Corporation shares published by Fortum Corporation.

Orion Calendar 2016–2017

Interim Report January–September 2016	Tue 25 Oct 2016
Financial Statement Release for 2016	Wed 8 Feb 2017
Annual General Meeting 2017	Planned to be held on Wed 22 Mar 2017
Interim Report January–March 2017	Wed 26 Apr 2017
Half-Yearly Report January–June 2017	Wed 19 Jul 2017
Interim Report January–September 2017	Thu 26 Oct 2017

The Financial Statements and Report by the Board of Directors for 2016 will be published on the Company's website at the latest in week 9/2017.



ORION

ORION
Building well-being